Back to News
Market Impact: 0.35
Xeris Biopharma Holdings, Inc. Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance to $395 Million to $405 Million
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Xeris Biopharma reported third-quarter 2026 revenue of $107.2 million, up 44% year over year, primarily driven by increased patient demand for Recorlev. Recorlev net revenue rose 93% year over year.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
XERS0.70
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook